323 related articles for article (PubMed ID: 30479461)
1. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer.
Cabrero-de Las Heras S; Martínez-Balibrea E
World J Gastroenterol; 2018 Nov; 24(42):4738-4749. PubMed ID: 30479461
[TBL] [Abstract][Full Text] [Related]
2. Chemokine‑ and chemokine receptor-based subtypes predict prognosis, immunotherapy and chemotherapy response in colorectal cancer patients.
Zhu W; Zhao S; Cheng X; Wu C; Liu Z; Huang J
Int Immunopharmacol; 2024 Jun; 134():112172. PubMed ID: 38703566
[TBL] [Abstract][Full Text] [Related]
3. Chemokines as Prognostic Factor in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.
Fellhofer-Hofer J; Franz C; Vey JA; Kahlert C; Kalkum E; Mehrabi A; Halama N; Probst P; Klupp F
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791414
[TBL] [Abstract][Full Text] [Related]
4. The Role of CXCL11 and its Receptors in Cancer: Prospective but Challenging Clinical Targets.
Wang J; Ouyang X; Zhu W; Yi Q; Zhong J
Cancer Control; 2024; 31():10732748241241162. PubMed ID: 38533911
[TBL] [Abstract][Full Text] [Related]
5. Pro-inflammatory cytokines and CXC chemokines as game-changer in age-associated prostate cancer and ovarian cancer: Insights from preclinical and clinical studies' outcomes.
Ullah A; Chen Y; Singla RK; Cao D; Shen B
Pharmacol Res; 2024 Jun; 204():107213. PubMed ID: 38750677
[TBL] [Abstract][Full Text] [Related]
6. The multifaceted role of the CXC chemokines and receptors signaling axes in ALS pathophysiology.
La Cognata V; Morello G; Guarnaccia M; Cavallaro S
Prog Neurobiol; 2024 Apr; 235():102587. PubMed ID: 38367748
[TBL] [Abstract][Full Text] [Related]
7. Chemokines and Their Receptors: Predictors of Therapeutic Potential in Tumor Microenvironment on Esophageal Cancer.
Huang CG; Liu Q; Zheng ST; Liu T; Tan YY; Peng TY; Chen J; Lu XM
Dig Dis Sci; 2024 May; 69(5):1562-1570. PubMed ID: 38580886
[TBL] [Abstract][Full Text] [Related]
8. The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.
Ullah A; Jiao W; Shen B
Cell Mol Biol Lett; 2024 May; 29(1):73. PubMed ID: 38745115
[TBL] [Abstract][Full Text] [Related]
9. The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care.
De Rosa M; Rega D; Costabile V; Duraturo F; Niglio A; Izzo P; Pace U; Delrio P
Therap Adv Gastroenterol; 2016 Nov; 9(6):861-886. PubMed ID: 27803741
[TBL] [Abstract][Full Text] [Related]
10. Targeting G protein-coupled receptor for pain management.
Li H; Wang R; Lu Y; Xu X; Ni J
Brain Circ; 2017; 3(2):109-113. PubMed ID: 30276310
[TBL] [Abstract][Full Text] [Related]
11. Differential Effects of Posttranslational Modifications of CXCL8/Interleukin-8 on CXCR1 and CXCR2 Internalization and Signaling Properties.
Vacchini A; Mortier A; Proost P; Locati M; Metzemaekers M; Borroni EM
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486423
[TBL] [Abstract][Full Text] [Related]
12. Vaccines for colorectal cancer: an update.
Sarvizadeh M; Ghasemi F; Tavakoli F; Sadat Khatami S; Razi E; Sharifi H; Biouki NM; Taghizadeh M
J Cell Biochem; 2019 Jun; 120(6):8815-8828. PubMed ID: 30536960
[TBL] [Abstract][Full Text] [Related]
13. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
14. Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment.
Zeng Q; Sun S; Li Y; Li X; Li Z; Liang H
Front Oncol; 2019; 9():1555. PubMed ID: 32117786
[No Abstract] [Full Text] [Related]
15. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
Gouverneur A; Coutureau J; Jové J; Rouyer M; Grelaud A; Duc S; Gérard S; Smith D; Ravaud A; Droz C; Bernard MA; Lassalle R; Forrier-Réglat A; Noize P;
Clin Colorectal Cancer; 2019 Mar; 18(1):e150-e162. PubMed ID: 30630730
[TBL] [Abstract][Full Text] [Related]
16. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Modest DP; Rivera F; Bachet JB; de Braud F; Pietrantonio F; Koukakis R; Demonty G; Douillard JY
Int J Cancer; 2019 Jul; 145(2):576-585. PubMed ID: 30614531
[TBL] [Abstract][Full Text] [Related]
17. CXCL2/CXCR2 axis induces cancer stem cell characteristics in CPT-11-resistant LoVo colon cancer cells via Gαi-2 and Gαq/11.
Chen MC; Baskaran R; Lee NH; Hsu HH; Ho TJ; Tu CC; Lin YM; Viswanadha VP; Kuo WW; Huang CY
J Cell Physiol; 2019 Jul; 234(7):11822-11834. PubMed ID: 30552676
[TBL] [Abstract][Full Text] [Related]
18. The Significance of CXCL1 and CXCL8 as Well as Their Specific Receptors in Colorectal Cancer.
Łukaszewicz-Zając M; Pączek S; Mroczko P; Kulczyńska-Przybik A
Cancer Manag Res; 2020; 12():8435-8443. PubMed ID: 32982437
[TBL] [Abstract][Full Text] [Related]
19. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
20. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
Liao W; Overman MJ; Boutin AT; Shang X; Zhao D; Dey P; Li J; Wang G; Lan Z; Li J; Tang M; Jiang S; Ma X; Chen P; Katkhuda R; Korphaisarn K; Chakravarti D; Chang A; Spring DJ; Chang Q; Zhang J; Maru DM; Maeda DY; Zebala JA; Kopetz S; Wang YA; DePinho RA
Cancer Cell; 2019 Apr; 35(4):559-572.e7. PubMed ID: 30905761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
